Huntington's disease (HD) is an inherited neurodegenerative disorder caused by the abnormal expansion of CAG trinucleotide repeats in the Huntingtin gene (HTT) located on chromosome 4. It is transmitted in an autosomal dominant manner and is characterized by motor dysfunction, cognitive decline, and emotional disturbances. To date, there are no curative treatments for HD have been developed; current therapeutic approaches focus on symptom relief and comprehensive care through coordinated pharmacological and nonpharmacological methods to manage the diverse phenotypes of the disease. International clinical guidelines for the treatment of HD are continually being revised in an effort to enhance care within a multidisciplinary framework. Additionally, innovative gene and cell therapy strategies are being actively researched and developed to address the complexities of the disorder and improve treatment outcomes. This review endeavours to elucidate the current and emerging gene and cell therapy strategies for HD, offering a detailed insight into the complexities of the disorder and looking forward to future treatment paradigms. Considering the complexity of the underlying mechanisms driving HD, a synergistic treatment strategy that integrates various factors-such as distinct cell types, epigenetic patterns, genetic components, and methods to improve the cerebral microenvironment-may significantly enhance therapeutic outcomes. In the future, we eagerly anticipate ongoing innovations in interdisciplinary research that will bring profound advancements and refinements in the treatment of HD.
Huntington Disease/pathology* ; Humans ; Genetic Therapy/methods* ; Animals ; Huntingtin Protein/genetics* ; Cell- and Tissue-Based Therapy/methods*

Movement disorder, as a presentation of an acute or chronic cerebrovascular disease (CVD) occur in less than five percent of CVD cases. Although a rare presentation of CVDs, stroke is a common etiology of secondary movement disorder. Hemichorea is particularly prevalent following stroke. The objectives of this report are to (1) present nine cases of sudden-onset hyperkinetic movement disorders manifested in acute and chronic stroke patients (2) emphasize the importance of early diagnosis by clinical signs and symptoms identified through computed tomography (CT) and magnetic resonance imaging (MRI), and (3) determine the different anatomic locations involved in this disorder. Hemichorea is the most common hyperkinetic movement disorder seen after stroke with a predilection in older age. It demonstrated that deep vascular lesions had a greater probability of developing movement disorder. Hemichorea-hemiballismus with abrupt onset should be approached as an acute stroke until other potential causes are ruled out. The exact pathophysiology of these abnormal movements remains unclear, although some theories propose dysfunction within the motor circuitry pathway. While many cases resolve spontaneously, medical or surgical interventions may be necessary to manage symptoms, potentially influencing long-term outcomes.

Human ; Male ; Female ; Aged: 65-79 Yrs Old ; Middle Aged: 45-64 Yrs Old ; Movement Disorders ; Chorea ; Hemiballismus ; Dyskinesias ; Stroke

Movement disorder, as a presentation of an acute or chronic cerebrovascular disease (CVD) occur in less than five percent of CVD cases. Although a rare presentation of CVDs, stroke is a common etiology of secondary movement disorder. Hemichorea is particularly prevalent following stroke. The objectives of this report are to (1) present nine cases of sudden-onset hyperkinetic movement disorders manifested in acute and chronic stroke patients (2) emphasize the importance of early diagnosis by clinical signs and symptoms identified through computed tomography (CT) and magnetic resonance imaging (MRI), and (3) determine the different anatomic locations involved in this disorder. Hemichorea is the most common hyperkinetic movement disorder seen after stroke with a predilection in older age. It demonstrated that deep vascular lesions had a greater probability of developing movement disorder. Hemichorea-hemiballismus with abrupt onset should be approached as an acute stroke until other potential causes are ruled out. The exact pathophysiology of these abnormal movements remains unclear, although some theories propose dysfunction within the motor circuitry pathway. While many cases resolve spontaneously, medical or surgical interventions may be necessary to manage symptoms, potentially influencing long-term outcomes.

Human ; Male ; Female ; Aged: 65-79 Yrs Old ; Middle Aged: 45-64 Yrs Old ; Movement Disorders ; Chorea ; Hemiballismus ; Dyskinesias ; Stroke

Systemic lupus erythematosus combined with chorea is relatively rare in China,and there are no unified diagnostic criteria or specific ancillary tests.Therefore,it is confirmed by exclusionary clinical diagnosis.To improve the understanding of this disease among rheumatologists,we report the clinical data of a patient with systemic lupus erythematosus combined with chorea admitted to the Department of Rheumatology and Immunology in the First Affiliated Hospital of Jinan University in January 2022.Furthermore,we review the relevant literature in the past 10 years and summarize the clinical features of these cases.
Humans ; Chorea/diagnosis* ; Lupus Erythematosus, Systemic/complications* ; China ; Hospitalization ; Hospitals

Humans ; Huntington Disease/diagnostic imaging* ; Brain/diagnostic imaging* ; Brain Mapping ; Magnetic Resonance Imaging

Huntington's disease (HD) is an autosomal dominantly-inherited neurodegenerative disease, which is caused by CAG trinucleotide expansion in exon 1 of the Huntingtin (HTT) gene. Although HD is a rare disease, its monogenic nature makes it an ideal model in which to understand pathogenic mechanisms and to develop therapeutic strategies for neurodegenerative diseases. Clustered regularly-interspaced short palindromic repeats (CRISPR) is the latest technology for genome editing. Being simple to use and highly efficient, CRISPR-based genome-editing tools are rapidly gaining popularity in biomedical research and opening up new avenues for disease treatment. Here, we review the development of CRISPR-based genome-editing tools and their applications in HD research to offer a translational perspective on advancing the genome-editing technology to HD treatment.
Humans ; Gene Editing ; Huntington Disease/therapy* ; CRISPR-Cas Systems/genetics* ; Neurodegenerative Diseases

Brain-lung-thyroid syndrome is a rare autosomal dominant disorder. More than 100 cases have been reported worldwide, but few cases have been reported in China. In December 2018, a boy with brain-lung-thyroid syndrome, aged 3 years and 10 months, was admitted to Xiangya Hospital of Central South University due to repeated cough for more than 3 years. In infancy of the boy, psychomotor retardation, repeated cough, and hypothyroidism were found. Gene detection showed that there was c.927delc heterozygous variation in NKX2-1 gene (NM-001079668: exon3: c.927delC). The variation of this gene locus has not been reported in relevant literature so far, which indicates a new mutation. According to the above clinical manifestations and examination results, the boy was diagnosed as brain-lung-thyroid syndrome, which mainly characterized by nervous system disorders, accompanied by respiratory manifestations and hypothyroidism. The boy was treated with oral dopasehydrazine to relieve tremor and levothyroxine sodium tablets to relieve hypothyroidism. Anti-infection, atomization, rehabilitation training and other symptomatic supporting treatment were also administered. The boy's language and movement have improved, the thyroid hormone level is normal, and there are still repeated respiratory tract infections.
Athetosis/genetics* ; Chorea ; Congenital Hypothyroidism/genetics* ; Cough ; Humans ; Male ; Respiratory Distress Syndrome, Newborn ; Thyroid Nuclear Factor 1/genetics*

OBJECTIVE: To explore the genetic basis for two Chinese pedigrees affected with Huntington disease and provide prenatal diagnosis for them. METHODS: Peripheral venous blood samples were collected from the probands. PCR and capillary gel electrophoresis were used to determine the number of CAG repeats in their IT15 gene. Pre-symptomatic testing was offered to their children and relatives, and prenatal diagnosis was provided to three pregnant women from the two pedigrees. RESULTS: The two probands, in addition with three asymptomatic members, were found to have a (CAG)n repeat number greater than 40. Upon prenatal diagnosis, the numbers of CAG repeats in two fetuses from pedigree 1 were determined as (16, 19) and (18, 19), both were within the normal range. A fetus from pedigree 2 was found to have a CAG repeat number of (15, 41), which exceeded the normal range. CONCLUSION Genetic testing can facilitate the diagnosis of Huntington disease and avoid further birth of affected children.
Child ; Female ; Genetic Testing ; Humans ; Huntington Disease/genetics* ; Nerve Tissue Proteins/genetics* ; Pedigree ; Pregnancy ; Prenatal Diagnosis

Chorea/etiology* ; Humans ; Lupus Erythematosus, Systemic/diagnosis* ; Phototherapy

INTRODUCTION: Nonketotic hyperglycemia among type 2 diabetic patients have recently been documented to cause the rare movement disorder called Hemichorea-hemiballism syndrome which is a hyperkinetic movement disorder presenting as a continuous, non-patterned, involuntary movements caused by a basal ganglia dysfunction. METHODS: A 76-year-old male with a known history of hypertension and no history of stroke and diabetes presented with a 10-day history of increasingly persistent involuntary movements of the right extremities. On admission, the patient was conscious with stable vital signs and unremarkable neurologic findings except for the involuntary flailing movements of the right extremities. Diagnostic testing revealed first documentation of hyperglycemia with brain MRI changes on T1 hyperintensity signals on the basal ganglia and T2/FLAIR weighted imaging showing mixed hypointense and hyperintense signals which is a classical MRI finding in patients with HC-HB syndrome caused by nonketotic hyperglycemia. The patient was treated for diabetes and was maintained on anti-dopaminergic medications for the uncontrollable involuntary movements. After five months, resolution of the hemiballism-hemichorea syndrome was noted after appropriate treatment. CONCLUSION: This case report highlights hemichoreahemiballism syndrome in a newly diagnosed type 2 diabetic patient who had normal glucose levels at presentation. The prompt recognition and correction of uncontrolled newly diagnosed diabetes and administration of anti-dopamine agents lead to a rapid improvement of symptoms, less neurologic sequelae and an overall favorable prognosis.
Chorea ; Dyskinesias ; Hyperglycemia ; Basal Ganglia Diseases ; Diabetes Mellitus, Type 2 ; Basal Ganglia